A real-world clinical study of pyrotinib maleate tablets in the treatment of her-2 positive breast cancer patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900021819

Enrollment

Unknown

Registered

2019-03-11

Start date

2019-03-10

Completion date

Unknown

Last updated

2019-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Case series:pyrotinib

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 years old male or female; 2. Advanced breast cancer patients with positive her-2 expression confirmed by pathological examination; 3. Patients with locally advanced her-2 positive breast cancer who were not treated with standard neoadjuvant regimens or were not eligible for standard neoadjuvant regimens were judged by the researchers; 4. Voluntarily joined the study and signed the informed consent; 5. The researchers believe that treatment can be beneficial.

Exclusion criteria

Exclusion criteria: 1. Has been confirmed to be allergic to pyrotinib and/or its excipients; 2. Pregnant or lactating women; 3. Patients with contraindications to pyrotinib were excluded; 4. Not suitable for inclusion according to the researcher.

Design outcomes

Primary

Measure	Time frame
PFS;	—

Countries

China

Contacts

Public ContactFeng Jifeng

42 Baiziting, Xuanwu District, Nanjing, Jiangsu, China?

fjif@vip.sina.com+86 13901581264

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026